Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 19/20 | 0.70 |
| ▸ | OPRK1 | P41145 | 15/20 | 0.70 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5765228 | 1.00 | OPRM1 (0.70) | OPRM1OPRK1OPRD1 | |
| SCHEMBL5792907 | 0.89 | OPRM1 (0.70) | OPRM1OPRK1OPRD1 | |
| SCHEMBL5792905 | 0.89 | OPRM1 (0.70) | OPRM1OPRK1OPRD1 | |
| SCHEMBL5764276 | 0.83 | OPRM1 (0.71) | OPRM1OPRK1OPRD1 | |
| SCHEMBL5764279 | 0.83 | OPRM1 (0.71) | OPRM1OPRK1OPRD1 | |
| SCHEMBL5766560 | 0.83 | OPRM1 (0.70) | OPRM1OPRK1OPRD1 | |
| SCHEMBL6369267 | 0.83 | OPRM1 (0.70) | OPRM1OPRK1OPRD1 | |
| SCHEMBL5766221 | 0.83 | OPRM1 (0.78) | OPRM1OPRK1OPRD1 | |
| SCHEMBL5766218 | 0.83 | OPRM1 (0.78) | OPRM1OPRK1OPRD1 | |
| SCHEMBL1705343 | 0.82 | OPRM1 (0.78) | OPRM1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007502808-A | — | — | 2007-02-15 | — | — | JP | claimed |
| EP-1658098-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA2DELTA LIGAND AND AN OPIOID RECEPTOR ANTAGONIST FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | claimed |
| EP-1658082-A1 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | claimed |
| WO-2005018645-A1 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | PFIZER PRODUCTS INC. (US) | 2005-03-03 | — | — | WO | claimed |
| WO-2005018670-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA2DELTA LIGAND AND AN OPIOID RECEPTOR ANTAGONIST FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | PFIZER PRODUCTS INC. (US) | 2005-03-03 | — | — | WO | claimed |
| US-20050043345-A1 | Pharmaceutical composition for the prevention and treatment of addiction in a mammal | PFIZER INC | 2005-02-24 | — | — | US | claimed |
| US-20050043327-A1 | Pharmaceutical composition for the prevention and treatment of addiction in a mammal | PFIZER INC | 2005-02-24 | — | — | US | claimed |
| US-20050032837-A1 | 4-Phenyl-piperidine compounds and their use as modulators of opioid receptors | PFIZER, INC. (US) | 2005-02-10 | — | — | US | claimed |
| US-20040204453-A1 | 4-Phenyl-piperidine compounds and their use as modulators of opioid receptors | PFIZER INC | 2004-10-14 | — | — | US | claimed |
| EP-1658082-A1 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | disclosed |
| EP-1658098-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA2DELTA LIGAND AND AN OPIOID RECEPTOR ANTAGONIST FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | Pfizer Products Inc. (US) | 2006-05-24 | — | — | EP | disclosed |
| EP-1615643-A1 | 4-PHENYL-PIPERIDINE COMPOUNDS AND THEIR USE AS MODULATORS OF OPIOID RECEPTORS | Pfizer Products Inc. (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2005018645-A1 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | PFIZER PRODUCTS INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005018670-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN ALPHA2DELTA LIGAND AND AN OPIOID RECEPTOR ANTAGONIST FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | PFIZER PRODUCTS INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20050043345-A1 | Pharmaceutical composition for the prevention and treatment of addiction in a mammal | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
| US-20050043327-A1 | Pharmaceutical composition for the prevention and treatment of addiction in a mammal | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
| US-20050032837-A1 | 4-Phenyl-piperidine compounds and their use as modulators of opioid receptors | PFIZER, INC. (US) | 2005-02-10 | — | — | US | disclosed |
| WO-2004089370-A1 | 4-PHENYL-PIPERIDINE COMPOUNDS AND THEIR USE AS MODULATORS OF OPIOID RECEPTORS | PFIZER PRODUCTS INC. (US) | 2004-10-21 | — | — | WO | disclosed |
| US-20040204453-A1 | 4-Phenyl-piperidine compounds and their use as modulators of opioid receptors | PFIZER INC | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032837-A1 | 4-Phenyl-piperidine compounds and their use as modulators of opioid receptors | OPRD1, OPRK1, OPRM1 | OPRM1 3/4885OPRK1 2/4885OPRD1 1/4885 |
| US-20040204453-A1 | 4-Phenyl-piperidine compounds and their use as modulators of opioid receptors | OPRD1, OPRK1, OPRM1 | OPRM1 3/4885OPRK1 2/4885OPRD1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.